Rare disease studies come with their own unique challenges, particularly limited patient populations. However, there are a number of adaptive clinical trial design strategies that can be used to mitigate the challenge of hard-to-recruit patient populations and associated trial risks. In this upcoming webinar, Valeria Mazzanti and Boaz Adler discuss four risk-mitigation tools they have previously deployed with sponsors and how each of these can help trial sponsors working with limited rare disease patient populations: 

• Sample Size Optimization  
• Sample Size Re-Estimation
• Phase II/III Seamless Designs
• Exact Statistical methodologies 

For more information about the series or reporting registration issues, please contact Nathan.trott@cytel.com.

To learn more about Cytel, click here.